Literature DB >> 14740149

Fluoxetine, but not sertraline or citalopram, potentiates the locomotor stimulant effect of cocaine: possible pharmacokinetic effects.

Paul J Fletcher1, Judy Sinyard, Mahnaz Salsali, Glen B Baker.   

Abstract

RATIONALE: The selective serotonin reuptake inhibitor (SSRI) fluoxetine enhances some of the behavioural effects of cocaine, including locomotor stimulation. While this effect has often been interpreted as evidence for a serotonergic component to the behavioural effects of cocaine, direct evidence for this hypothesis is lacking. One alternative explanation is that fluoxetine, by inhibiting cytochrome P450 (CYP) enzymes, interferes with the metabolism of cocaine.
OBJECTIVES: These experiments were undertaken to: 1) compare the effects of fluoxetine with those of two other SSRIs, sertraline and citalopram, on cocaine-induced locomotor activity, 2) examine the effects of fluoxetine on cocaine-stimulated locomotion in rats depleted of serotonin (5-hydroxytryptamine; 5-HT), and 3) determine the effect of fluoxetine on cocaine levels in the brain.
METHODS: Locomotor activity was measured, using photocell based activity monitors, in rats habituated to those monitors. Depletion of 5-HT was achieved by injecting 5,7-dihydroxytryptamine (5,7-DHT) into the dorsal and median raphe nuclei. Cocaine levels in whole brain were measured using high-performance liquid chromatography with ultraviolet detection.
RESULTS: In experiment 1, 5 mg/kg fluoxetine enhanced the ability of 10 and 15 mg/kg cocaine to increase locomotor activity. Neither citalopram nor sertraline (5 and 10 mg/kg) altered the stimulant effect of 10 mg/kg cocaine. Experiment 2 showed that this effect of fluoxetine was also apparent in rats with large and widespread depletion of brain 5-HT levels. The 5-HT depletion also failed to alter the response to cocaine itself. In experiment 3, brain levels of cocaine were elevated in rats pretreated with fluoxetine compared with rats that received cocaine alone.
CONCLUSION: Fluoxetine enhanced the ability of cocaine to increase locomotor activity. This effect appears not to depend upon increasing 5-HT function since fluoxetine was also effective in rats with substantial 5-HT depletions, and two other SSRIs did not alter the effects of cocaine. Fluoxetine-treated rats had higher brain levels of cocaine than rats treated with cocaine alone. This effect suggests that fluoxetine slows the metabolism of cocaine, perhaps by inhibition of CYP enzymes involved in metabolizing cocaine. The results also indicate that 5-HT reuptake inhibition may not play a prominent role in mediating the stimulant effects of cocaine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14740149     DOI: 10.1007/s00213-003-1747-9

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  47 in total

1.  Selective destruction of brain serotonin neurons by 5,7-dihydroxytryptamine increases responding for a conditioned reward.

Authors:  P J Fletcher; K M Korth; J W Chambers
Journal:  Psychopharmacology (Berl)       Date:  1999-12       Impact factor: 4.530

2.  Modulation of the discriminative stimulus properties of cocaine: comparison of the effects of fluoxetine with 5-HT1A and 5-HT1B receptor agonists.

Authors:  P M Callahan; K A Cunningham
Journal:  Neuropharmacology       Date:  1997-03       Impact factor: 5.250

3.  The potentiating effect of sertraline and fluoxetine on amphetamine-induced locomotor activity is not mediated by serotonin.

Authors:  T L Sills; A J Greenshaw; G B Baker; P J Fletcher
Journal:  Psychopharmacology (Berl)       Date:  1999-04       Impact factor: 4.530

4.  Serotonergic lesions alter cocaine-induced locomotor behavior and stress-activation of the mesocorticolimbic dopamine system.

Authors:  B A Morrow; R H Roth
Journal:  Synapse       Date:  1996-07       Impact factor: 2.562

Review 5.  Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update.

Authors:  Alex Hemeryck; Frans M Belpaire
Journal:  Curr Drug Metab       Date:  2002-02       Impact factor: 3.731

6.  Modification of behavioral effects of cocaine by selective serotonin and dopamine uptake inhibitors in squirrel monkeys.

Authors:  R D Spealman
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  Participation of cytochromes P4502B and P4503A in cocaine toxicity in rat hepatocytes.

Authors:  T S Poet; C A McQueen; J R Halpert
Journal:  Drug Metab Dispos       Date:  1996-01       Impact factor: 3.922

8.  Increase in extracellular serotonin produced by uptake inhibitors is enhanced after chronic treatment with fluoxetine.

Authors:  J J Rutter; C Gundlah; S B Auerbach
Journal:  Neurosci Lett       Date:  1994-04-25       Impact factor: 3.046

9.  Differential metabolism of alprazolam by liver and brain cytochrome (P4503A) to pharmacologically active metabolite.

Authors:  H V Pai; S C Upadhya; S J Chinta; S N Hegde; V Ravindranath
Journal:  Pharmacogenomics J       Date:  2002       Impact factor: 3.550

10.  The selective serotonin(1A)-receptor antagonist WAY 100635 blocks behavioral stimulating effects of cocaine but not ventral striatal dopamine increase.

Authors:  Christian P Müller; Maria A De Souza Silva; Gail DePalma; Carlos Tomaz; Robert J Carey; Joseph P Huston
Journal:  Behav Brain Res       Date:  2002-08-21       Impact factor: 3.332

View more
  3 in total

1.  Citalopram enhances cocaine's subjective effects in rats.

Authors:  Paul L Soto; Takato Hiranita; Jonathan L Katz
Journal:  Behav Pharmacol       Date:  2009-12       Impact factor: 2.293

2.  Fluoxetine does not alter the ability of dopamine D(1)- and D(2)-like agonists to substitute for cocaine in squirrel monkeys.

Authors:  Paul L Soto; Jonathan L Katz
Journal:  Pharmacol Biochem Behav       Date:  2008-12-07       Impact factor: 3.533

3.  Citalopram for treatment of cocaine use disorder: A Bayesian drop-the-loser randomized clinical trial.

Authors:  Robert Suchting; Charles E Green; Constanza de Dios; Jessica Vincent; F Gerard Moeller; Scott D Lane; Joy M Schmitz
Journal:  Drug Alcohol Depend       Date:  2021-09-23       Impact factor: 4.492

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.